Association of variants in the ABCB1, CYP2C19 and CYP2C9 genes for Juvenile Myoclonic Epilepsy

被引:0
|
作者
Jara-Prado, Aurelio [1 ]
Guerrero-Camacho, Jorge Luis [1 ]
Angeles-Lopez, Quetzalli Denisse [2 ]
Ochoa-Morales, Adriana [1 ]
de Montellano, David Jose Davila-Ortiz [1 ]
Ramirez-Garcia, Miguel Angel [1 ]
Breda-Yepes, Michelle [3 ]
Duron, Reyna M. [4 ]
Delgado-Escueta, Antonio V. [5 ]
Barrios-Gonzalez, Diego A. [3 ]
Martinez-Juarez, Iris E. [3 ]
机构
[1] Natl Inst Neurol & Neurosurg, Genet Dept, Mexico City, Mexico
[2] UNAM, Fac Estudios Super Cuautitlan, Cuautitlan, Mexico
[3] Natl Inst Neurol & Neurosurg, Epilepsy Clin, Mexico City, Mexico
[4] Univ Tecnol Ctr Amer UNITEC, Tegucigalpa, Honduras
[5] UCLA, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA
关键词
Juvenile Myoclonic Epilepsy; Risk Factor; Genetic Variants; ABCB1; CYPC219; genes; Genes Interaction; BLOOD-BRAIN-BARRIER; BINDING CASSETTE TRANSPORTERS; MDR1; GENE; ULCERATIVE-COLITIS; CYTOCHROMES P450; DRUG-RESISTANCE; P-GLYCOPROTEIN; POLYMORPHISMS; HAPLOTYPES; C3435T;
D O I
10.1007/s10072-023-07124-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Juvenile myoclonic epilepsy (JME) is the most common of the generalized genetic epilepsies, with multiple causal and susceptibility genes; however, its etiopathogenesis is mainly unknown. The toxic effects caused by xenobiotics in cells occur during their metabolic transformation, mainly by enzymes belonging to cytochrome P450. The elimination of these compounds by transporters of the ABC type protects the central nervous system, but their accumulation causes neuronal damage, resulting in neurological diseases. The present study has sought the association between single nucleotide genetic variants of the CYP2C9, CYP2C19, and ABCB1 genes and the development of JME in patients compared to healthy controls. The CC1236 and GG2677 genotypes of ABCB1 in women; allele G 2677, genotypes GG 2677 and CC 3435 in men; the CYP2C19*2A allele, and the CYP2C19*3G/A genotype in both sexes were found to be risk factors for JME. Furthermore, carriers of the TTGGCC genotype combination of the ABCB1 gene (1236/2677/3435) have a 10.5 times higher risk of developing JME than non-carriers. Using the STRING database, we found an interaction between the proteins encoded by these genes and other possible proteins. These findings indicate that the CYP450 system and ABC transporters could interact with other genes in the JME.
引用
收藏
页码:1635 / 1643
页数:9
相关论文
共 50 条
  • [41] Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene- gene interactions on warfarin therapy
    Khalighi, Koroush
    Cheng, Gang
    Mirabbasi, Seyedabbas
    Khalighi, Bahar
    Wu, Yin
    Fan, Wuqiang
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 43 (01) : 124 - 129
  • [42] Cytochrome p450 CYP2C9 and CYP2C19 genetic polymorphisms in croatian children with epilepsy
    Gjergja, R.
    Cvitanovic-Sojat, L.
    Bielen, L.
    Sojat, T.
    Stefanovic, M.
    EPILEPSIA, 2006, 47 : 182 - 183
  • [43] Individualized Phenytoin Therapy for Japanese Pediatric Patients With Epilepsy Based on CYP2C9 and CYP2C19 Genotypes
    Yamamoto, Yoshiaki
    Takahashi, Yukitoshi
    Imai, Katsumi
    Miyakawa, Kou
    Ikeda, Hiroko
    Ueda, Yuki
    Yamaguchi, Tokito
    Nasu, Hirosato
    Ohtani, Hideyuki
    Shigematsu, Hideo
    Kagawa, Yoshiyuki
    Inoue, Yushi
    THERAPEUTIC DRUG MONITORING, 2015, 37 (02) : 229 - 235
  • [44] Kinetic analysis of fluvastatin metabolism by CYP2C9 and its allelic variants, CYP2C9*2 and CYP2C9*3
    Einolf, HJ
    Fischer, V
    DRUG METABOLISM REVIEWS, 2003, 35 : 191 - 191
  • [45] Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5′-hydroxylation
    Iida, I
    Miyata, A
    Arai, M
    Hirota, M
    Akimoto, M
    Higuchi, S
    Kobayashi, K
    Chiba, K
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) : 7 - 9
  • [46] Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements (vol 32, pg 641, 2007)
    Saraeva, R. B.
    Paskaleva, I. D.
    Doncheva, E.
    Eap, C. B.
    Ganev, V. S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (01) : 93 - 93
  • [47] INFLUENCE OF CYP 2C9 AND CYP2C19 VARIANTS ON VENLAFAXINE DISPOSITION
    Lei, A.
    Borobia, A. M.
    Fudio, S.
    Laosa, O.
    Duque, B.
    Guerra, P.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 82 - 82
  • [48] Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro
    Stage, Tore Bjerregaard
    Graff, Magnus
    Wong, Susan
    Rasmussen, Louise Ladebo
    Nielsen, Flemming
    Pottegard, Anton
    Brosen, Kim
    Kroetz, Deanna L.
    Khojasteh, Cyrus
    Damkier, Per
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (03) : 510 - 519
  • [49] DISTRIBUTION OF THE CYP2C19*2, CYP2C19*3 AND CYP2C19*4 GENE VARIANTS IN A ROMANIAN POPULATION
    Buzoianu, A. D.
    Trifa, A. P.
    Popp, R. A.
    Militaru, C. F.
    Bocsan, C., I
    Popp, I., V
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 80 - 80
  • [50] Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population
    Krasniqi, Valon
    Dimovski, Aleksandar
    Bytyqi, Hasime Qorraj
    Eftimov, Aleksandar
    Simicevic, Livija
    Bozina, Nada
    ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2017, 68 (03): : 180 - 184